• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $420 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-30 Mln

Jasper Therapeutics Inc. (JSPR) Share Price

$29.36

As on 28-Mar-2024 16:18 EDT

up-down-arrow $0.541.87%

  • Prev Close info

    $28.82

  • Day's Openinfo

    $29.99

  • Today's Highinfo

    $31.00

  • Today's Lowinfo

    $29.36

  • Today's Volumeinfo

    95,945

  • 52 Week rangeinfo

    $4.00 - 31.00

Please wait...

Jasper Therapeutics Inc. (JSPR) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Jasper Therapeutics (JSPR)
272.12 39.61 375.85 57.85 -33.27 -- --
S&P BSE Sensex
1.95 0.76 2.24 27.75 14.54 14.07 12.73
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 28-Mar-2024  |  #As on 26-Oct-2023
2023
2022
Jasper Therapeutics (JSPR)
63.35 -93.85
S&P Small-Cap 600
13.89 -17.42
S&P BSE Sensex
18.74 4.44

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Jasper Therapeutics Inc. (JSPR) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Jasper Therapeutics Inc. (JSPR)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Jasper Therapeutics Inc. (JSPR)

        President, CEO & Director

        Mr. Ronald A. Martell

        Co-Founder, Chair of Scientific Advisory Board & Director

        Dr. Judith Anne Shizuru M.D., Ph.D.

        Headquarters

        Redwood City, CA

        FAQs for Jasper Therapeutics Inc. (JSPR)

        The total asset value of Jasper Therapeutics Inc. (JSPR) stood at $ 95 Mln as on 31-Dec-23

        The share price of Jasper Therapeutics Inc. (JSPR) is $29.36 (NASDAQ) as of 28-Mar-2024 16:18 EDT. Jasper Therapeutics Inc. (JSPR) has given a return of -33.27% in the last 3 years.

        Jasper Therapeutics Inc. (JSPR) has a market capitalisation of $ 420 Mln as on 28-Mar-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Jasper Therapeutics Inc. (JSPR) is 5.32 times as on 28-Mar-2024, a 0.61% premium to its peers’ median range of 3.30 times.

        Since, TTM earnings of Jasper Therapeutics Inc. (JSPR) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Jasper Therapeutics Inc. (JSPR) and enter the required number of quantities and click on buy to purchase the shares of Jasper Therapeutics Inc. (JSPR).

        Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California. Address: 2200 Bridge Pkwy, Redwood City, CA, United States, 94065

        The CEO & director of Mr. Ronald A. Martell. is Jasper Therapeutics Inc. (JSPR), and CFO & Sr. VP is Dr. Judith Anne Shizuru M.D., Ph.D..

        The promoters of Jasper Therapeutics Inc. (JSPR) have pledged 0% of the total equity as on Sep-23.

        Jasper Therapeutics Inc. (JSPR) Ratios
        Return on equity(%)
        -112.67
        Return on capital employed(%)
        -106.67
        Debt-to-equity ratio
        0.04
        Dividend yield(%)
        --

        No, TTM profit after tax of Jasper Therapeutics Inc. (JSPR) was $-30 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $420.13 Mln
        • Revenue (TTM)revenue-information $3.49 Mln
        • Earnings (TTM) earning-information $-30.34 Mln
        • Cash date-information $86.89 Mln
        • Total Debt info $2.79 Mln
        • Insider's Holding 6.15%
        • Liquidity liquidity High
        • 52 Week range week-range $4.00 - 31.00
        • Shares outstanding share-outstanding 15,063,900
        • 5 Years Aggregate:

          CFO: $-149.87 Mln

          EBITDA: $-186.42 Mln

          Net Profit: $-144.30 Mln

        About The Company

        • IPO Date 24-Sep-2021
        • President, CEO & Director Mr. Ronald A. Martell
        • Co-Founder, Chair of Scientific Advisory Board & Director Dr. Judith Anne Shizuru M.D., Ph.D.
        • Listing key-listing NASDAQ: JSPR
        • Country United States
        • Headquarters headquarters Redwood City, CA
        • Website website https://www.jaspertherapeutics.com/
        • Business

          Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases,...  such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California. Address: 2200 Bridge Pkwy, Redwood City, CA, United States, 94065  Read more

        share-fund-plan-icon